BayMedica
Jim Kealey has over 25 years of work experience in the biotechnology industry. Jim started their career as an Associate Scientist/Post Doc at Geron Corporation in 1995. Jim then worked at Kosan Biosciences as an Associate Director, leading projects on polyketide synthase expression and engineering. In 2007, they joined Biosearch Technologies as a Synthetic Biology Consultant. In 2008, they became the Director of Molecular Biology at Amyris Inc, where they managed groups of researchers in various technical areas. In 2013, they joined Intrexon Corporation as a Senior Director, a position they held until 2018. Currently, they are the VP of Research and Development at BayMedica.
Jim Kealey earned a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, from 1982 to 1986. Jim then pursued a Ph.D. in Pharmaceutical Chemistry at the University of California, San Francisco, from 1989 to 1994.
This person is not in any teams
This person is not in any offices
BayMedica
BayMedica Inc., a division of InMed Pharmaceuticals (Nasdaq: INM) is a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable, and proprietary platform to produce high quality, rare cannabinoids for consumer applications and cannabinoid-derived new chemical entities for pharmaceutical applications.